Proactive Investors - Run By Investors For Investors

Epistem clinical trial go-ahead marks important milestone - Chairman

Ian Gilham, chairman of Epistem Holdings (LON:EHP) says clinical trials of its genedrive diagnostic test for Hepatitis C (HCV) will start immediately and “probably run until the third of fourth quarter of this year.”

Once the studies are finalised and results collated the company will begin the registration process towards a CE marked product which Gilham anticipates will be “sometime in 2017.”

The qualitative HCV test was developed in collaboration with Inserm, the French National Institute of Health and Medical Research, under a €6m EU supported programme and cleared for clinical trials by the Institut Pasteur in Paris.

Meet Victoria Oil & Gas plc, Avation PLC and Greatland Gold plc at our event, London, 07 September 2017. Register here »
View full GDR profile View Profile

Genedrive PLC Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use